JP6266023B2 - 黄斑変性症の処置における新規トラップ - Google Patents

黄斑変性症の処置における新規トラップ Download PDF

Info

Publication number
JP6266023B2
JP6266023B2 JP2015555214A JP2015555214A JP6266023B2 JP 6266023 B2 JP6266023 B2 JP 6266023B2 JP 2015555214 A JP2015555214 A JP 2015555214A JP 2015555214 A JP2015555214 A JP 2015555214A JP 6266023 B2 JP6266023 B2 JP 6266023B2
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
cycloalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015555214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505637A (ja
JP2016505637A5 (enExample
Inventor
ジョン クリフォード チャバラ，
ジョン クリフォード チャバラ，
トーマス エー． ジョーダン，
トーマス エー． ジョーダン，
ケ−チン リン，
ケ−チン リン，
ジョン ジー． グリーソン，
ジョン ジー． グリーソン，
ウィリアム エー． キニー，
ウィリアム エー． キニー，
Original Assignee
アルデイラ セラピューティクス， インコーポレイテッド
アルデイラ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルデイラ セラピューティクス， インコーポレイテッド, アルデイラ セラピューティクス， インコーポレイテッド filed Critical アルデイラ セラピューティクス， インコーポレイテッド
Publication of JP2016505637A publication Critical patent/JP2016505637A/ja
Publication of JP2016505637A5 publication Critical patent/JP2016505637A5/ja
Application granted granted Critical
Publication of JP6266023B2 publication Critical patent/JP6266023B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2015555214A 2013-01-25 2014-01-21 黄斑変性症の処置における新規トラップ Expired - Fee Related JP6266023B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756778P 2013-01-25 2013-01-25
US61/756,778 2013-01-25
PCT/US2014/012356 WO2014116593A1 (en) 2013-01-25 2014-01-21 Novel traps in the treatment of macular degeneration

Publications (3)

Publication Number Publication Date
JP2016505637A JP2016505637A (ja) 2016-02-25
JP2016505637A5 JP2016505637A5 (enExample) 2017-02-23
JP6266023B2 true JP6266023B2 (ja) 2018-01-24

Family

ID=51227964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015555214A Expired - Fee Related JP6266023B2 (ja) 2013-01-25 2014-01-21 黄斑変性症の処置における新規トラップ

Country Status (13)

Country Link
US (2) US10111862B2 (enExample)
EP (1) EP2948436A4 (enExample)
JP (1) JP6266023B2 (enExample)
KR (1) KR20150120380A (enExample)
CN (1) CN105228989A (enExample)
AU (1) AU2014209585A1 (enExample)
CA (1) CA2898869A1 (enExample)
HK (1) HK1217490A1 (enExample)
IL (1) IL239736A0 (enExample)
MX (1) MX2015009444A (enExample)
RU (1) RU2015126015A (enExample)
SG (1) SG11201505599YA (enExample)
WO (1) WO2014116593A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2393768T3 (es) 2005-05-26 2012-12-27 Neuron Systems, Inc Derivado de quinolina para el tratamiento de enfermedades retinianas
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
WO2014100425A1 (en) 2012-12-20 2014-06-26 Aldexa Therapeutics, Inc. Peri-carbinols
HK1217439A1 (zh) 2013-01-23 2017-01-13 Aldeyra Therapeutics, Inc. 与毒性醛相关的疾病和治疗
WO2016021706A1 (ja) * 2014-08-08 2016-02-11 カズマパートナーズ株式会社 縮合複素環化合物
CN118724806A (zh) * 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
CN109069530A (zh) 2016-02-28 2018-12-21 奥尔德拉医疗公司 用环糊精治疗过敏性眼部病状
MX2018013472A (es) 2016-05-09 2019-02-28 Aldeyra Therapeutics Inc Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
WO2018170476A1 (en) * 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
AU2018348174A1 (en) 2017-10-10 2020-04-23 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
AU2019319740A1 (en) 2018-08-06 2021-03-25 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020068986A1 (en) 2018-09-25 2020-04-02 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
JP7706758B2 (ja) 2019-03-26 2025-07-14 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN114828857B (zh) * 2019-09-09 2024-11-12 联邦高等教育系统-匹兹堡大学 通过激活tfeb恢复视网膜色素上皮细胞的溶酶体功能的方法
AU2020419515A1 (en) * 2019-12-30 2022-05-19 The National Institutes of Pharmaceutical R&D Co., Ltd. Tricyclic compound, and preparation method therefor and medical use thereof
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2086186A (en) 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
GB1435721A (en) 1972-05-18 1976-05-12 Lilly Industries Ltd Benzoxazole derivatives
SU509046A1 (ru) 1975-02-21 1984-06-23 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
GB8610981D0 (en) 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
AU641052B2 (en) 1990-11-02 1993-09-09 Aventisub Ii Inc. 3-amidoindolyl derivatives
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
US5597823A (en) 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
US5742954A (en) 1996-11-22 1998-04-28 Softub, Inc. Electrically powered spa jet unit
US6191127B1 (en) 1997-05-02 2001-02-20 Schering Aktiengesellschaft Substituted heterocycles and their use in medicaments
EP1080068A1 (en) 1998-03-12 2001-03-07 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
AU1735001A (en) 1999-12-10 2001-06-18 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
US6569879B2 (en) * 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20060281821A1 (en) 2003-03-14 2006-12-14 Krzysztof Palczewski Retinoid replacements and opsin agonists and methods for the use thereof
EP1621199B8 (en) 2003-04-18 2011-01-19 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
JP4110324B2 (ja) 2003-10-15 2008-07-02 宇部興産株式会社 新規インダゾール誘導体
AU2004293105B2 (en) 2003-11-20 2010-09-09 Othera Holding, Inc. Amelioration of macular degeneration and other ophthalmic diseases
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
US20080176952A1 (en) 2004-02-17 2008-07-24 Rando Robert R Management of Ophthalmologic Disorders, Including Macular Degeneration
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2006002473A1 (en) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
JP2008518913A (ja) 2004-10-28 2008-06-05 メルク エンド カムパニー インコーポレーテッド 代謝調節型グルタミン酸受容体のピリミジン及びキノリン増強因子
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
ES2393768T3 (es) 2005-05-26 2012-12-27 Neuron Systems, Inc Derivado de quinolina para el tratamiento de enfermedades retinianas
ES2437997T3 (es) 2006-04-14 2014-01-15 Prana Biotechnology Limited Método de tratamiento de la degeneración macular relacionada con la edad (AMD)
CA2658793A1 (en) 2006-07-25 2008-02-07 Daniel Dumas Quinoline derivatives
UA110089C2 (uk) 2007-10-05 2015-11-25 Ак'Юсела Інк. Алкоксисполуки для лікування нейродегенеративних хвороб
AU2009282076A1 (en) 2008-08-12 2010-02-18 Sirtris Pharmaceuticals, Inc. Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators
WO2010133672A1 (en) 2009-05-20 2010-11-25 Clanotech Ab Derivatives of quinoline-3-carboxylic acid and their medical use
WO2011008202A1 (en) 2009-07-15 2011-01-20 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
CA2782015C (en) * 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
CN103562186B (zh) 2011-01-12 2017-02-15 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
EP2670439B1 (en) 2011-01-31 2019-03-13 PVAC Medical Technologies Ltd. Active principle for mitigating undesired medical conditions
WO2014100425A1 (en) 2012-12-20 2014-06-26 Aldexa Therapeutics, Inc. Peri-carbinols
HK1217439A1 (zh) * 2013-01-23 2017-01-13 Aldeyra Therapeutics, Inc. 与毒性醛相关的疾病和治疗

Also Published As

Publication number Publication date
US20150344447A1 (en) 2015-12-03
RU2015126015A (ru) 2017-03-03
US10111862B2 (en) 2018-10-30
SG11201505599YA (en) 2015-08-28
EP2948436A4 (en) 2016-07-13
IL239736A0 (en) 2015-08-31
EP2948436A1 (en) 2015-12-02
CN105228989A (zh) 2016-01-06
AU2014209585A1 (en) 2015-07-23
US20190125729A1 (en) 2019-05-02
MX2015009444A (es) 2016-04-15
JP2016505637A (ja) 2016-02-25
CA2898869A1 (en) 2014-07-31
WO2014116593A1 (en) 2014-07-31
HK1217490A1 (zh) 2017-01-13
KR20150120380A (ko) 2015-10-27

Similar Documents

Publication Publication Date Title
JP6266023B2 (ja) 黄斑変性症の処置における新規トラップ
JP2016503797A (ja) ペリ−カルビノール
US10202348B2 (en) Compositions and methods of treating retinal disease
JP2020079305A (ja) 毒性アルデヒド関連疾患および処置
HUE030848T2 (hu) Benzilidén-guanidin-származékok és terápiás alkalmazásuk fehérjék hibás feltekeredésével összefüggõ betegségek kezelésében
JP2008531558A (ja) 新規なリポオキシゲナーゼ阻害剤
TW200526205A (en) Nitrogen-containing heterocyclic compound, and medicine containing such compound as effective ingredient
HK1113797B (en) Quinoline derivative for the treatment of retinal diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171219

R150 Certificate of patent or registration of utility model

Ref document number: 6266023

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees